Name
AS Bravo Pharmaceuticals
Registry code
14159974
VAT number
EE101938974
Type
AS - Joint Stock Company
Status
Registered
Foundation date
29.11.2016 (8)
Financial year
01.01-31.12
Capital
335 337.00 €
Activity
86909 - Other healthcare activities not classified elsewhere
-
-
-
-
-
-
-
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Reena Singh
| 20% - 68 170.00 EUR | Board member | - | Shareholder |
| Rakesh Pandey
| 80% - 267 167.00 EUR | Board member | - | FounderShareholder |
| Nishant Kumar
| - | - | - | Board member |
| Ivo Nagel
| - | - | - | Chairman of the board |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Competence Centre for Cancer Research AS 11015418 | 65% - 32 500.00 EUR | - | - | Shareholder |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q4 | 5 421.31 € | 4 683.26 € | 4 024.68 € | 1 |
| 2024 Q3 | - | 5 223.11 € | 4 571.22 € | 1 |
| 2024 Q2 | 17 100 € | 7 415 € | 4 844.49 € | 1 |
| 2024 Q1 | 10 674.39 € | 7 012.62 € | 4 791.49 € | 1 |
| 2023 Q4 | 14 556.66 € | 7 123.14 € | 4 685.49 € | 1 |
| 2023 Q3 | - | 6 807.84 € | 5 697.15 € | 1 |
| 2023 Q2 | - | 4 141.31 € | 3 636.73 € | 1 |
| 2023 Q1 | - | 5 485.08 € | 4 590.69 € | 1 |
| 2022 Q4 | - | 5 518.67 € | 4 613.79 € | 1 |
| 2022 Q3 | - | 5 376.45 € | 4 574.19 € | 1 |
| 2022 Q2 | 4 000 € | 5 377.45 € | 4 574.19 € | 1 |
| 2022 Q1 | 15 775 € | 5 453.08 € | 4 574.19 € | 1 |
| 2021 Q4 | 4 000 € | 5 528.27 € | 4 620.39 € | 1 |
| 2021 Q3 | 6 041.66 € | 5 011.18 € | 4 027.65 € | 1 |
| 2021 Q2 | 5 116.66 € | 4 475.82 € | 3 754.38 € | 1 |
| 2021 Q1 | - | 4 136.41 € | 3 754.38 € | 2 |
| 2020 Q4 | - | 4 076.41 € | 3 765.51 € | 2 |
| 2020 Q3 | 17 024.27 € | 2 903.4 € | 3 536.89 € | 2 |
| 2020 Q2 | 7 933.34 € | 5 483.39 € | 4 135.88 € | 2 |
| 2020 Q1 | 29 333.33 € | 2 337.85 € | 2 067.94 € | 2 |
